{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:32:23Z","timestamp":1790573543608,"version":"4.1.0"},"reference-count":42,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,7]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>For dose escalation, patients with mCRPC received intramuscular PrCa VBIR (adenovirus vector and plasmid DNA expressing prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), and prostate stem cell antigen (PSCA)) with or without immune checkpoint inhibitors (ICIs, tremelimumab 40 or 80 mg with or without sasanlimab 130 or 300 mg, both subcutaneous). For dose expansion, patients with mCRPC received recommended phase 2 dose (RP2D) of PrCa VBIR plus tremelimumab 80 mg and sasanlimab 300 mg; patients with BCR received PrCa VBIR plus tremelimumab 80 mg (Cohort 1B-BCR) or tremelimumab 80 mg plus sasanlimab 130 mg (Cohort 5B-BCR) without androgen deprivation therapy (ADT). The primary endpoint was safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ninety-one patients were treated in dose escalation (mCRPC=38) and expansion (BCR=35, mCRPC=18). Overall, treatment-related and immune-related adverse events occurred in 64 (70.3%) and 39 (42.9%) patients, with fatigue (40.7%), influenza-like illness (30.8%), diarrhea (23.1%), and immune-related thyroid dysfunction (19.8%) and rash (15.4%), as the most common. In patients with mCRPC, the objective response rate (ORR, 95% CI) was 5.6% (1.2% to 15.4%) and the median radiographic progression-free survival (rPFS) was 5.6 (3.5 to not estimable) months for all; the ORR was 16.7% (3.6% to 41.4%) and 6-month rPFS rate was 45.5% (24.9% to 64.1%) for those who received RP2D with measurable disease (n=18). 7.4% of patients with mCRPC achieved a \u226550% decline in baseline PSA (PSA-50), with a median duration of 4.6 (1.2\u201345.2) months. In patients with BCR, 9 (25.7%) achieved PSA-50; the median duration of PSA response was 3.9 (1.9\u20134.2) and 10.1 (6.9\u201328.8) months for Cohorts 5B-BCR and 1B-BCR. Overall, antigen specific T-cell response was 88.0% to PSMA, 84.0% to PSA, and 80.0% to PSCA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PrCa VBIR overall demonstrated safety signals similar to other ICI combination trials; significant side effects were seen in some patients with BCR. It stimulated antigen-specific immunity across all cohorts and resulted in modest antitumor activity in patients with BCR without using ADT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02616185\">NCT02616185<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005702","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T19:02:00Z","timestamp":1683658920000},"page":"e005702","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02616185","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02616185","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02616185","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-0390","authenticated-orcid":false,"given":"Karen A","family":"Autio","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S","family":"Higano","sequence":"additional","affiliation":[{"name":"University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nordquist","sequence":"additional","affiliation":[{"name":"Urology Cancer Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard J","family":"Appleman","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-3531","authenticated-orcid":false,"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Durham, North Carolina, USA"},{"name":"UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Northwell Health Cancer Institute, New Hyde Park, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Babiker","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Vogelzang","sequence":"additional","affiliation":[{"name":"Comprehens Cancer Centers of Nevada, Las Vegas, Nevada, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip M","family":"Prasad","sequence":"additional","affiliation":[{"name":"Morristown Medical Center\/Atlantic Health System, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Schweizer","sequence":"additional","affiliation":[{"name":"University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A","family":"Madan","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Billotte","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Cavazos","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlaith","family":"Bogg","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam","family":"Chan","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Cho","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Zheng","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Yu","family":"Tang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hollingsworth","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A","family":"Kern","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P","family":"Petrylak","sequence":"additional","affiliation":[{"name":"Yale University Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"2025100301395838000_11.3.e005702.1","unstructured":"U.S. Food and Drug Administration . FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. Available: www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication [Accessed Feb 2023]."},{"key":"2025100301395838000_11.3.e005702.2","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-018-0712-z","article-title":"Immunotherapy in prostate cancer: teaching an old dog new tricks","volume":"20","author":"Comiskey","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2025100301395838000_11.3.e005702.3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/14760584.2015.1118348","article-title":"Prospects for the future of prostate cancer vaccines","volume":"15","author":"Madan","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2025100301395838000_11.3.e005702.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071752","article-title":"Immunotherapy in prostate cancer","volume":"12","author":"Fay","year":"2020","journal-title":"Cancers"},{"key":"2025100301395838000_11.3.e005702.5","doi-asserted-by":"crossref","DOI":"10.1007\/s11934-019-0931-3","article-title":"Immunotherapy in metastatic castration-resistant prostate cancer: past and future strategies for optimization","volume":"20","author":"Reimers","year":"2019","journal-title":"Curr Urol Rep"},{"key":"2025100301395838000_11.3.e005702.6","article-title":"Emerging treatments for metastatic castration-resistant prostate cancer: immunotherapy, PARP inhibitors, and PSMA-targeted approaches","volume":"23","author":"Marshall","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"2025100301395838000_11.3.e005702.7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-030-32656-2_7","article-title":"Immunological complexity of the prostate cancer microenvironment influences the response to immunotherapy","volume":"1210","author":"Prokhnevska","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2025100301395838000_11.3.e005702.8","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000433"},{"key":"2025100301395838000_11.3.e005702.9","unstructured":"US Food and Drug Administration . Highlights of prescribing information: provenge (sipuleucel-T). 2019. Available: www.fda.gov\/media\/78511\/download [Accessed Feb 2023]."},{"key":"2025100301395838000_11.3.e005702.10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100301395838000_11.3.e005702.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"2025100301395838000_11.3.e005702.12","unstructured":"National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: prostate cancer v1.2022, 2021. Available: www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf [Accessed 7 Oct 2021]."},{"key":"2025100301395838000_11.3.e005702.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"2025100301395838000_11.3.e005702.14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4161\/hv.21660","article-title":"Cancer vaccines: are we there yet?","volume":"8","author":"Hanna","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"2025100301395838000_11.3.e005702.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2257"},{"key":"2025100301395838000_11.3.e005702.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.06.067"},{"key":"2025100301395838000_11.3.e005702.17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/21645515.2017.1364322","article-title":"Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations","volume":"13","author":"Gatti-Mays","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2025100301395838000_11.3.e005702.18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ucl.2020.07.004","article-title":"The potential role for immunotherapy in biochemically recurrent prostate cancer","volume":"47","author":"Bilusic","year":"2020","journal-title":"Urol Clin North Am"},{"key":"2025100301395838000_11.3.e005702.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02031"},{"key":"2025100301395838000_11.3.e005702.20","unstructured":"Small EJ , Gerritsen WR , Rolland F , et al . A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Abstract presented at: American Society for Clinical Oncology Genitourinary Cancers Symposium; 26\u201328 Feb 2009; Orlando, FL, USA. Abstract 7."},{"key":"2025100301395838000_11.3.e005702.21","unstructured":"Higano CS , Saad F , Curti BD , et al . A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Abstract presented at: American Society for Clinical Oncology Genitourinary Cancers Symposium; 26\u201328 Feb 2009; Orlando, FL, USA. Abstract LBA150. Available: media.corporate-ir.net\/media_files\/irol\/98\/98399\/09Feb_VITAL1_ASCO_GU-final.pdf"},{"key":"2025100301395838000_11.3.e005702.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9187-3"},{"key":"2025100301395838000_11.3.e005702.23","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31802f5d33"},{"key":"2025100301395838000_11.3.e005702.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1842"},{"key":"2025100301395838000_11.3.e005702.25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.11.6305-6313.2003"},{"key":"2025100301395838000_11.3.e005702.26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302675"},{"key":"2025100301395838000_11.3.e005702.27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00262-022-03245-x","article-title":"Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens","volume":"72","author":"Cho","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2025100301395838000_11.3.e005702.28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100301395838000_11.3.e005702.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0063"},{"key":"2025100301395838000_11.3.e005702.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3372"},{"key":"2025100301395838000_11.3.e005702.31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000655"},{"key":"2025100301395838000_11.3.e005702.32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju268"},{"key":"2025100301395838000_11.3.e005702.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1780"},{"key":"2025100301395838000_11.3.e005702.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2025100301395838000_11.3.e005702.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1068"},{"key":"2025100301395838000_11.3.e005702.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206"},{"key":"2025100301395838000_11.3.e005702.37","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9060623","article-title":"Cancer vaccines for genitourinary tumors: recent progresses and future possibilities","volume":"9","author":"Maiorano","year":"2021","journal-title":"Vaccines"},{"key":"2025100301395838000_11.3.e005702.38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.9.4635"},{"key":"2025100301395838000_11.3.e005702.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.073"},{"key":"2025100301395838000_11.3.e005702.40","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.067"},{"key":"2025100301395838000_11.3.e005702.41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019252"},{"key":"2025100301395838000_11.3.e005702.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.01.006"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:40:09Z","timestamp":1759480809000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,22]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/jitc-2022-005702"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005702","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}